These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 10674778)

  • 41. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
    DeVincenzo JP; Hirsch RL; Fuentes RJ; Top FH
    Bone Marrow Transplant; 2000 Jan; 25(2):161-5. PubMed ID: 10673674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current strategies in the prevention of respiratory syncytial virus disease.
    Paes BA
    Paediatr Respir Rev; 2003 Mar; 4(1):21-7. PubMed ID: 12615029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Int; 2005 Aug; 47(4):397-403. PubMed ID: 16091076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Respiratory syncytial virus: concerns and control.
    McCarthy CA; Hall CB
    Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
    [No Abstract]   [Full Text] [Related]  

  • 50. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
    Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis.
    Numa A
    J Paediatr Child Health; 2000 Oct; 36(5):422-7. PubMed ID: 11036794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L; García L; García I; Concepción CB
    P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.
    Prescott WA; Doloresco F; Brown J; Paladino JA
    Pharmacoeconomics; 2010; 28(4):279-93. PubMed ID: 20131925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.